Latest / Decera Clinical Education Oncology Podcast
Uncovering Safety and Signposts to the Future: AEs With HER2-Targeted ADCs and Future Applications
In this episode, Catherine Fahey, MD, PhD; Alexandra Leary, MD, PhD; Funda Meric-Bernstam, MD; and Zev A. Wainberg, MD, discuss the evolving safety considerations and future directions of HER2-targeted antibody–drug conjugates (ADCs) across genitourinary, gastrointestinal, and gynecologic cancers.
Toxicity Profiles of HER2-Targeted ADCs: Common and serious adverse events such as ILD/pneumonitis, neuropathy, and cytopenia across ADCs
On-Target vs Off-Target Effects: How linker design, payload type, and drug-to-antibody ratio (DAR) contribute to toxicity
Combination Therapy Considerations…
The skinny
The skinny isn't ready yet — notes appear once the transcript is processed.